Fulgent Genetics: Cash-Rich Deep Value Play Facing Strategic Crossroads After a Pandemic Windfall
Overview
Fulgent Genetics stands as a cash-rich holding company with high potential yet significant challenges, split between growing but unprofitable Laboratory Services and speculative Therapeutic Development. The company’s financial fortress—cash and securities exceeding its market capitalization—contrasts with operating losses and investor concerns over capital allocation (especially related-party transactions). The sum-of-the-parts analysis reveals intrinsic value well above market price, offering investors net cash at a discount with substantial upside if execution and pipeline success materialize. Catalysts include clinical trial data, strategic deals, and new contract wins, with risks centering on profitability, execution, and governance.